Second Genome Certified as Great Place to Work®
SOUTH SAN FRANCISCO, Calif., July 31, 2018
SOUTH SAN FRANCISCO, Calif., July 31, 2018 /PRNewswire/ -- Second Genome, Inc., a leader in the development of novel therapeutics derived from the human microbiome, was certified as a great workplace last week by the independent analysts at Great Place to Work®. Second Genome earned this credential based on extensive ratings provided by its employees in anonymous surveys, a summary of which can be found online at http://reviews.greatplacetowork.com/second-genome.
"I am proud of our employees for their ownership over our company culture, and their endless energy in striving to improve Second Genome each and every day," said Glenn Nedwin, Ph.D., MoT, president and CEO of Second Genome. "It is only with the effort and investment of all our team members that we are able to create a great place to work - one where all employees come to work each day knowing they are making a difference. This certification is a great way to recognize the impact our team members have had on our company culture."
"Our company culture has evolved so much over the last year - it's been wonderful to be a part of this energy our employees have created," added Jim Sjoerdsma, Executive Vice President, Human Resources. "I'm thrilled to see that through this team effort, we have built a company where team members look forward to coming in to work each day, and are able to be at their best. This is a great success for us as an organization, and a milestone we will build on."
Added Sarah Lewis-Kulin, vice president at Great Place to Work Certification & List Production, "According to our study, 91 percent of Second Genome employees say it is a great workplace."
About Second Genome
Second Genome is a clinical-stage biopharmaceutical company developing innovative therapies derived from the human microbiome. Second Genome's mission is to transform lives with protein, peptide and/or metabolite therapeutics for human disease. Second Genome has built a novel platform for microbiome drug discovery, which includes one of the world's largest, dynamic, curated and organized digital database of microbes correlated to metadata, using both proprietary and published data. The team has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The company leverages its microbiome analysis platform along with its biology and clinical expertise to generate insightful findings that can accelerate unique development programs, by elucidating the role of the microbiome in human health conditions. In 2018, Second Genome is advancing its lead program, SGM-1019, into a Phase 2 clinical trial in NASH, and plans to file an IND for its second clinical candidate, SG-2-0776.
Please visit www.secondgenome.com for more information.
About Great Place to Work®
Great Place to Work® is the global authority on high-trust, high-performance workplace cultures. Through proprietary assessment tools, advisory services, and certification programs, including Best Workplaces lists and workplace reviews, Great Place to Work® provides the benchmarks, framework, and expertise needed to create, sustain, and recognize outstanding workplace cultures. In the United States, Great Place to Work® produces the annual Fortune "100 Best Companies to Work For®" list and a series of Great Place to Work® Best Workplaces lists including lists for Millennials, Women, Diversity, Small and Medium Companies and over a half dozen different industry lists.
SOURCE Second Genome